We also showed that cervical cancers with mutations in the KMT2C and LRP1B genes have an increased TMB, and our data indicate that KMT2C and LRP1B gene mutations may serve as biomarkers to forecast therapeutic reactions. This evidence concerns the gene LRP1B and cervical cancer.